ArticleMicrobial cell factories2025
Conversion and upgrading of syringate by Acinetobacter baylyi ADP1.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLignin holds great potential as an abundant and sustainable source of aromatic compounds, offering a viable alternative to fossil-based resources for producing chemicals and materials. Biological upgrading of lignin-derived aromatics can lead to more comprehensive lignocellulose utilization, thereby enhancing the overall feasibility of production. However, exploring a broader range of potential microbial hosts, pathways, and enzymes is crucial for developing efficient conversion processes. In particular, improving the conversion of S-lignin-related aromatics, such as syringate, remains a key area for future research.
resultsIn this study, we aimed to investigate the conversion of S-lignin-related syringate in Acinetobacter baylyi ADP1 by exploiting its native vanillate demethylase, VanAB. We discovered that the wild-type strain can efficiently O-demethylate syringate to 3-O-methylgallate (3MGA) and then to gallate, revealing a previously unknown activity of VanAB of A. baylyi ADP1. Conversion dynamics and in vitro characterization showed that VanAB prefers syringate as a substrate over 3MGA. Overexpression of vanAB resulted in simultaneous conversion of syringate and 3MGA, but negatively impacted growth, potentially due to toxic side product formaldehyde and redox imbalance caused by high NADH consumption of the O-demethylation reactions. Native vanAB expression resulted in 3MGA accumulation if syringate was available. We took advantage of this by constructing a strain with heterologous expression of galA, a gallate dioxygenase from Pseudomonas putida KT2440, and demonstrated the conversion of the intermediate 3MGA into 2-pyrone-4,6,-dicarboxylate (PDC), a precursor for high-quality polyesters.
conclusionsIn this study, we discovered a previously unknown activity of syringate conversion in A. baylyi ADP1. By adjusting the expression level of vanAB, syringate can be directed either into gallate or 3MGA, which could be further converted into PDC through the heterologous expression of galA. Our results further highlight the potential and versatility of A. baylyi ADP1 for the conversion and upgrading of lignin-related aromatic compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.